Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Copernicus Therapeutics Inc.

http://cgsys.com/

Latest From Copernicus Therapeutics Inc.

Deal Watch: Castle Creek Likes Partner Fibrocell Enough To Buy It

Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.

Deals Business Strategies

Gene Therapy: The Next Big Thing?

Investors' and Big Pharmas' hitherto frosty view of gene-based medicines may be starting to thaw, at least in places, warmed by clinical progress and a smattering of deals. Is there any real potential in this market? Until the first FDA approval, no-one's expecting any real heat. But there are companies which are enjoying limited success in the early stages, whose experience most likely reflects where at least the near-term potential of gene-based medicines lie.

BioPharmaceutical Business Strategies

Venture Philanthropy: The New Venture Capital?

Non-profit organizations' growing support for industry drug development does more than fill a funding gap. It brings disease-knowledge, patient-access and an understanding of the end-market that few traditional VCs can offer.

BioPharmaceutical Strategy

Oxxon Pharmaccines Inc.

One of the challenges surrounding the development of new vaccines has been inducing a strong enough immune response to protect the recipient from future infections, or to eradicate existing infection. The founding scientists of Oxxon Pharmaccines found that a particular combination of immunizations, using different vectors to deliver the same antigen in a sequence dependent upon priming and timing, created a high T-cell response. The scientists filed a patent around their so-called {Prime-Boost} technology, which has potential in a whole range of diseases, including hepatitis B and melanoma.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register